Select Anticoagulants (Vitamin K antagonists)/Selected Direct-Acting Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
As your medicine treats your Hepatitis C, your liver may start to work better and process your blood thinner faster.
What might happen:
The effects of your warfarin may decrease, which can increase your risk of a blood clot.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. You may need to have your bleeding times checked more often. If you have any signs of bleeding, such as bleeding from your gums, nosebleeds, unusual bruising, or dark stools, contact your doctor right away.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.DeCarolis DD, Chen YC, Westanmo AD, Conley C, Gravely AA, Khan FB. Decreased warfarin sensitivity among patients treated with elbasvir and grazoprevir for hepatitis C infection. Am J Health Syst Pharm 2019 Sep 1; 76(17):1273-1280.
- 2.DeCarolis DD, Westanmo AD, Chen YC, Boese AL, Walquist MA, Rector TS. Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin. Ann Pharmacother 2016 Nov;50(11):909-917.
- 3.Badri PS, Dutta S, Wang H, Podsadecki TJ, Polepally AR, Khatri A, Zha J, Chiu YL, Awni WM, Menon RM. Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir. Antimicrob Agents Chemother 2015 Oct 12;60(1):105-14.
- 4.Menon RM, Badri PS, Wang T, Polepally AR, Zha J, Khatri A, Wang H, Hu B, Coakley EP, Podsadecki TJ, Awni WM, Dutta S. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol 2015 Jul;63(1):20-9.
- 5.Puglisi GM, Smith SM, Jankovich RD, Ashby CR Jr, Jodlowski TZ. Paritaprevir/ritonavir/ombitasvir/dasabuvir plus ribavirin therapy and inhibition of the anticoagulant effect of warfarin: a case report. J Clin Pharm Ther 2017 Feb;42(1):115-118.
- 6.Peterson D, Van Ermen A. Increased warfarin requirements in a patient with chronic hepatitis C infection receiving sofosbuvir and ribavirin. Am J Health Syst Pharm 2017 Jun 15;74(12):888-892.
- 7.Britnell SR, Willets AE, Vanderman AJ, Woodard CL, Britt RB. Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans. Pharmacotherapy 2016 Nov;36(11):1173-1179.
- 8.Rindone JP, Mellen CK. Reduction in warfarin effect associated with sofosbuvir-velpatasvir. Am J Health Syst Pharm 2017 Sep 01; 74(17):1308-1311.
- 9.de Lorenzo-Pinto A, Gimenez-Manzorro A, Rodriguez-Gonzalez CG, Ahumada-Jimenez A, Herranz-Alonso A, Marzal-Alfaro MB, Sanjurjo-Saez M. Decreased INR after acenocoumarol, ombitasvir/paritaprevir/ritonavir and dasabuvir co-administration. J Clin Pharm Ther 2016 Aug;41(4):444-446.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.